Evaluation of renal function in patients with cirrhosis: Where are we now?

被引:30
|
作者
Rognant, Nicolas [1 ,2 ,3 ]
Lemoine, Sandrine [1 ,2 ]
机构
[1] Hosp Civils Lyon, Dept Nephrol, Lyon, France
[2] Univ Lyon 1, F-69008 Lyon, France
[3] Univ Bristol, Sch Biochem, Bristol BS8 1TD, Avon, England
关键词
Cirrhosis; Glomerular filtration rate; Formula; Estimation; Agreement; Plasma creatinine; Cystatin C; GLOMERULAR-FILTRATION-RATE; GELATINASE-ASSOCIATED LIPOCALIN; PLASMA CYSTATIN-C; SERUM CREATININE; LIVER-TRANSPLANTATION; MEDICAL PROGRESS; INULIN-CLEARANCE; DIAGNOSTIC-VALUE; KIDNEY-FUNCTION; DISEASE;
D O I
10.3748/wjg.v20.i10.2533
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the clinical context of the patients with liver cirrhosis, accurate evaluation of the renal function is potentially crucial. Indeed, it can lead to early diagnosis of both acute kidney injury and chronic kidney disease and to reliable characterization of the renal status of the patient before performing a liver transplantation. Despite some limitations, the assay of serum creatinine (SCr) is universally used to estimate glomerular filtration rate (GFR) because of its wide availability, its simplicity and because it is inexpensive. Nevertheless, several reports show that the value of this assay to estimate GFR is strongly challenged in cirrhotic patients, especially in patients with liver failure and/or severely impaired renal function. This has led to seek new alternatives to estimate more reliably the GFR in these patients. Although the reference methods, based on the utilization of exogenous markers, allow measuring GFR and thereby constitute the "gold standard" to evaluate renal function, they are not feasible in routine clinical practice. Several studies have shown that a cystatin C (CysC) based formula perform better than the SCr-based estimates in cirrhotic patients and the estimation of GFR by these formulas could therefore lead to optimize the management of the patients. A new estimate based on CysC has been recently developed using a large number of patients and the first results regarding the evaluation of its performance are promising, making this new formula the best candidate for a reference estimate of the renal function in cirrhotic patients. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:2533 / 2541
页数:9
相关论文
共 50 条
  • [21] 'Where we are now'
    Donaldson, J
    FIDDLEHEAD, 2002, (212): : 62 - 64
  • [22] WHERE WE ARE NOW
    NIBLETT, WR
    STUDIES IN HIGHER EDUCATION, 1983, 8 (02) : 105 - 110
  • [23] WHERE ARE WE NOW
    JULIAN, DG
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 14 : S57 - &
  • [24] Where are we now?
    Farham, Bridget
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2016, 106 (04): : 4 - 4
  • [25] Where are we now?
    Hanchard, NA
    WEST INDIAN MEDICAL JOURNAL, 1998, 47 (04): : 123 - 124
  • [26] WHERE ARE WE NOW?
    Freudenberger, Erica
    LIBRARY JOURNAL, 2021, 146 (02) : 30 - 32
  • [27] WHERE ARE WE NOW
    NAKAJIMA, S
    SCIENCE OF SUPERCONDUCTIVITY AND NEW MATERIALS, 1989, 18 : 3 - 7
  • [28] The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka, Anna M.
    Szczylik, Cezary
    Rini, Brian
    EXPERT REVIEW OF ANTICANCER THERAPY, 2014, 14 (09) : 983 - 999
  • [29] Where are we now?
    Jones, Alan
    INTERNATIONAL GAS ENGINEERING AND MANAGEMENT, 2007, 47 (08): : 8 - 9
  • [30] WHERE WE ARE NOW
    WEINBERG, S
    SCIENCE, 1973, 180 (4083) : 276 - 278